CD Bioparticles releases exosomes targeting medical aesthetics
Key takeaways
- CD Bioparticles released plant- and animal-derived exosomes for cosmetic applications.
- The portfolio targets skin repair, aging, pigmentation, and hair follicle rejuvenation.
- Exosome innovation is growing as brands explore plant-based alternatives to human-derived materials.

CD Bioparticles has launched a product portfolio of exosomes designed for the beauty industry. The lineup is said to help repair skin barriers, reduce signs of aging, lighten hyperpigmentation, and rejuvenate hair follicles, and is positioned as particularly attractive for medical aesthetics and sensitive-skin applications.
The range, Exosomes for Cosmetics, includes research-grade vesicles, derived from plant and animal cells, that work by carrying biomolecules like proteins and lipids between cells. This natural process degrades with age, and boosting communication between the cells helps skin tissue heal and regenerate more effectively.
“Many current skin treatment methods have not yet achieved an ideal balance between medical rehabilitation and cosmetic needs,” CD Bioparticles says, noting that exosomes may help bridge that gap by offering both healing and beautifying effects.
According to the drug delivery company, exosomes can easily cross tissue barriers, and the body’s immune system cannot clear them as quickly, making them a promising alternative to traditional cosmetic ingredients.
Exosomes also have a unique lipid barrier structure that allows for targeted active compound delivery, which the company says helps improve product performance and localized skin results.
Clinical bridge?
Environmental factors, such as UV rays, pollution, and climate conditions, can lead to skin instability and dysfunction. When disrupted, CD Bioparticles says the skin can take longer to heal wounds, age prematurely, and manifest abnormal pigmentation, hair loss, and various immune-related or connective tissue disorders.
The company positions exosomes’ safety and compatibility with human skin as one of the compounds’ key advantages in targeting disrupted skin.
The portfolio includes plant- and animal-derived exosomes for cosmetic manufacturers.Compared to synthetic nanomaterials, CD Bioparticles says exosomes are biodegradable, biocompatible, and show very low toxicity and immunogenicity — immune reactivity from the body. This makes them especially useful for medical aesthetics and formulas for sensitive skin, where reducing irritation and side effects is prioritized.
The company offers a variety of cosmetic exosome products, including options derived from plant extracts and fermentation for beauty manufacturers wanting to align with growing demands for vegan cosmetics.
Exosome innovation picks up
The personal care industry has advanced innovation and regulatory readiness for exosomes in the past few years. Consumer demand for longevity-inspired anti-aging skin care continues to grow, and companies are increasingly turning to the extracellular vesicles for their formulations.
Last year, Personal Care Insights reported on a wave of cosmetics containing human-derived exosomes, and the legal blind spots dermatologists warned us would allow manufacturers to overlook safety.
Plant-based exosomes have emerged as an alternative to skirt these concerns. However, cosmetic chemicals manufacturer Seppic notes that it is challenging for brands to rely on a precise and reproducible concentration derived from plant sources that comply with international regulations.
To target this, the company recently announced that it has quantified the exosome concentration in its plant-based Celtosome ingredients, giving brands a precise and reproducible metric to work with.
Earlier this year, Dermatologica also introduced a leave-on product that contains plant-based exosomes and enzyme-derived exfoliation ingredients.










